Where I see patients (4)
Immune modulation with RANKL blockade through denosumab treatment in patients with cancer.
Cancer immunology research
Oral Toxicities of PSMA-Targeted Immunotherapies for The Management of Prostate Cancer.
Clinical genitourinary cancer
TCR signaling promotes formation of an STS1-Cbl-b complex with pH-sensitive phosphatase activity that suppresses T cell function in acidic environments.
Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition
ORR by RECIST version 1.1
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior ...
A positive response is defined as a ≥40% increase in the number of infiltrating cluster of differentiation 3 (CD3) + T cells between the pre-treatment biopsy at baseline and the post-treatment RP specimen. Thus, a negative respons...
An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination ...